$100 per share is only AUD $23 billion (USD $18 billion). Myokardia got sold to BMS for USD $13 billion late last year for a Phase 3 heart condition drug affecting 1 in 500 people vs OA around 1 in 10 people. BMS just submitted their NDA last week for it so yes they are ahead in terms of clinical development. $100 does seem crazy to think about today but it is not outside the realm of possibility since PPS has the potential to be the holy grail treatment for OA - “the last frontier for big diseases without a treatment”
- Forums
- ASX - By Stock
- PAR
- Pfizer's Tanezumab receives almost unanimous rejection by FDA Adcom
Pfizer's Tanezumab receives almost unanimous rejection by FDA Adcom, page-15
-
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PAR (ASX) to my watchlist
|
|||||
Last
28.0¢ |
Change
-0.010(3.45%) |
Mkt cap ! $97.94M |
Open | High | Low | Value | Volume |
29.0¢ | 29.5¢ | 28.0¢ | $40.10K | 140.9K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
5 | 135929 | 28.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
28.5¢ | 20969 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
5 | 135929 | 0.280 |
1 | 22475 | 0.275 |
7 | 102859 | 0.270 |
2 | 384000 | 0.265 |
4 | 21233 | 0.260 |
Price($) | Vol. | No. |
---|---|---|
0.285 | 20969 | 2 |
0.290 | 72464 | 1 |
0.300 | 3984 | 2 |
0.305 | 55100 | 3 |
0.310 | 22870 | 4 |
Last trade - 16.10pm 09/07/2024 (20 minute delay) ? |
Featured News
PAR (ASX) Chart |